Lipid Nanoparticle Delivery for CNS Gene Therapy

Overview

Lipid nanoparticles (LNPs) are non-viral delivery vehicles composed of ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG), traditionally used for mRNA delivery (e.g., COVID-19 vaccines by Moderna and Pfizer-BioNTech). For neurodevelopmental epilepsies (NDEs), LNPs represent a promising alternative to [AAV vectors](/technologies/aav-vectors) for delivering genetic payloads to the CNS, with potential advantages in manufacturing scale-up, payload capacity, and redosing capability[@akinc2020].

Unlike AAVs, LNPs can carry a wider range of payloads — mRNA, siRNA, ASOs, CRISPR-Cas9 components, and base editing machinery — making them versatile for multiple therapeutic modalities in NDE gene therapy programs.

Mechanism of Delivery

Structure and Composition

LNP formulations typically consist of four lipid components:

| Component | Role | Typical mol% |
|-----------|------|-------------|
| Ionizable lipid | Payload encapsulation, endosomal escape | 50-60% |
| Phospholipid | Structural stability, bilayer formation | 10-15% |
| Cholesterol | Membrane rigidity, fusion kinetics | 35-40% |
| PEG-lipid | Stealth properties, circulation half-life | 1-2% |

Overview

Lipid nanoparticles (LNPs) are non-viral delivery vehicles composed of ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG), traditionally used for mRNA delivery (e.g., COVID-19 vaccines by Moderna and Pfizer-BioNTech). For neurodevelopmental epilepsies (NDEs), LNPs represent a promising alternative to [AAV vectors](/technologies/aav-vectors) for delivering genetic payloads to the CNS, with potential advantages in manufacturing scale-up, payload capacity, and redosing capability[@akinc2020].

Unlike AAVs, LNPs can carry a wider range of payloads — mRNA, siRNA, ASOs, CRISPR-Cas9 components, and base editing machinery — making them versatile for multiple therapeutic modalities in NDE gene therapy programs.

Mechanism of Delivery

Structure and Composition

LNP formulations typically consist of four lipid components:

| Component | Role | Typical mol% |
|-----------|------|-------------|
| Ionizable lipid | Payload encapsulation, endosomal escape | 50-60% |
| Phospholipid | Structural stability, bilayer formation | 10-15% |
| Cholesterol | Membrane rigidity, fusion kinetics | 35-40% |
| PEG-lipid | Stealth properties, circulation half-life | 1-2% |

The ionizable lipid is the key determinant of delivery efficiency. At low pH (during formulation), the lipid is positively charged, enabling complexation with negatively charged nucleic acids. At physiological pH, it becomes neutral, reducing toxicity and opsonization. After cell uptake and endosomal acidification, the lipid becomes protonated, disrupting the endosomal membrane and releasing the payload into the cytoplasm[@tenchov2021].

Blood-Brain Barrier Crossing

The primary challenge for LNP-mediated CNS delivery is crossing the [blood-brain barrier](/entities/blood-brain-barrier) (BBB). LNPs are typically too large (~80-100 nm) for free paracellular diffusion, so BBB crossing relies on specific transcytosis pathways:

• Anti-transferrin receptor (TfR) antibodies: Cross-react with mouse and human TfR, enabling transcytosis
• ApoE mimetic peptides: Bind to LDL receptor family, leveraging the natural CNS entry pathway of lipoproteins
• GM1 ganglioside-targeting: Some formulations use molecule(s) that bind gangliosides on brain endothelium

Advantages for NDE Gene Therapy

| Advantage | Description | NDE Relevance |
|-----------|-------------|--------------|
| Payload flexibility | Can deliver mRNA, ASOs, CRISPR components, siRNA, base editors | Versatile across multiple NDE modalities |
| Manufacturing scale | Synthetic chemistry allows scalable, reproducible production | Critical for rare disease commercial viability |
| Redosing capability | No pre-existing immunity issue (unlike AAVs) | Allows repeat dosing as children grow |
| Cargo capacity | No hard size limit like AAV (~4.7kb) | Can deliver larger CRISPR systems, base editors |
| Immunogenicity | Lower immunogenicity than AAV in repeat dosing | Important for pediatric applications |
| Cost | Significantly lower manufacturing cost than viral vectors | Better for rare disease economics |
| Tropism control | Surface engineering can target specific cell types | Enables targeting of GABAergic interneurons for SCN1A |

Challenges and Limitations

NDE-Specific Applications

mRNA-Based Gene Upregulation

For Dravet syndrome ([SCN1A](/genes/scn1a) haploinsufficiency), LNPs delivering SCN1A mRNA could restore Nav1.1 channel expression in inhibitory neurons. Unlike CRISPR-activation approaches that modify gene regulation, mRNA delivery provides a direct protein replacement strategy[@poh2022].

Key programs to track:

• Alnylam Pharmaceuticals has explored CNS LNP-mRNA delivery for neurological diseases
• Several academic groups (UCSF, Boston Children's Hospital) are investigating LNP-mRNA for NDEs
• mRNA-1273/LNP technology originators (Moderna) have CNS programs

CRISPR-Cas9 Editing

LNPs can co-deliver Cas9 mRNA and guide RNA for permanent gene correction. This approach is particularly relevant for:

• SCN1A correction: Direct fixing of disease-causing variants
• UBE3A restoration: Precise correction of the Angelman deletion/rearrangement
• KCNQ2 gain-of-function: For dominant-negative variants

ASO Co-Delivery

While ASOs are typically delivered without viral vectors, LNP encapsulation can improve CNS delivery and reduce peripheral exposure. This is particularly relevant for:

• GTX-102 (Angelman/UBE3A-ATS targeting) — could benefit from LNP formulation improvements
• Next-generation ASOs with improved CNS penetration

Comparison to AAV for NDE Applications

| Factor | AAV | LNP |
|--------|-----|-----|
| BBB penetration | Moderate (serotype-dependent) | Low-to-moderate (engineered) |
| Payload capacity | ~4.7kb (limiting for large genes) | No hard limit (mRNA or DNA) |
| Immunogenicity | High (pre-existing antibodies common) | Low |
| Redosing | Limited by immune response | Fully repeatable |
| Manufacturing | Complex, batch-variable, expensive | Scalable, reproducible |
| Duration | Long-term (years in neurons) | Transient (weeks-months) |
| Cost | High | Lower |
| Cell-type specificity | Serotype-dependent, hard to control | Surface-engineerable |

Key Research Groups and Companies

| Entity | Focus | Status |
|--------|-------|--------|
| Alnylam Pharmaceuticals | LNP-mRNA CNS delivery | Research |
| Moderna | CNS LNP programs | Pipeline |
| Precision BioSciences | LNP-CRISPR delivery | Preclinical |
| Stanford/Boston Children's | LNP-mRNA for epilepsy | Academic research |
| Denali Therapeutics | LNP-BBB crossing (TV platform) | Clinical (non-NDE) |
| Roche | LNP-delivered ASOs | Clinical |

Future Directions

Key Open Questions

Cross-Links

• [AAV Vectors](/technologies/aav-vectors) — competing viral delivery platform](/technologies)
• [Exosome Delivery](/technologies/exosome-cns-delivery) — alternative non-viral approach](/technologies)
• [Gene Therapy for Neurodevelopmental Epilepsy](/technologies/gene-therapy-neurodevelopmental-epilepsy) — hub page](/technologies)
• [SCN1A Gene](/genes/scn1a) — Dravet syndrome target](/genes)
• [UBE3A Gene](/genes/ube3a) — Angelman syndrome target](/genes)
• [Focused Ultrasound Neuromodulation](/technologies/focused-ultrasound-neuromodulation) — BBB opening combination strategy